A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

Schizophrenia Clinical Trial

Official title:

A Randomized, Single-blind, Two-period Crossover to Investigate the Effect of SEP-363856 on the Pharmacokinetics of Metformin in Subjects With Schizophrenia.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04865835
• Other study ID #: SEP361-110
• Status: Completed
• Phase: Phase 1
• Start date: May 12, 2021
• Est. completion date: May 3, 2022

Study information

• Verified date: May 2022
• Source: Sunovion
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A clinical trial study to determine the effect of an investigational drug (SEP-363856) has on the way that the drug Metformin travels through the body in people with schizophrenia. This clinical trial will have approximately 24 subjects both male and female 18 year of age and older. This study will be conducted in approximately 2 study sites in the United States.

Description:

This is a randomized, single-blind, two-period crossover study in which each subject will receive both treatments and therefore act as their own control to minimize confounding covariates within the study population. Randomizing subjects to treatment sequence will assist with reducing the potential order effects that might confound the findings if all the subjects received the same treatment sequence. The single-blind method is used to keep subjects blind to treatment assignment throughout the study period, in order to avoid possible influence of the psychological factors of subjects on study assessments. This clinical study will evaluate whether SEP 363856 influences the PK of a concomitantly administered OCT2 substrate, metformin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: May 3, 2022
• Est. primary completion date: May 3, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male or female subject between 18 and 65 years of age, inclusive, at the time of informed consent.
• Subject meets Diagnostic and Statistical Manual of Mental Disorders (DSM 5) criteria for a primary diagnosis of schizophrenia as established by clinical interview (using the DSM 5 as a reference and confirmed using the Structured Clinical Interview for DSM 5, Clinical Trials Version [SCID CT]).
• Subject must have a Clinical Global Impressions - Severity Scale (CGI S) score = 4 (normal to moderately ill) at Screening.
• Subject must have a Positive and Negative Syndrome Scale (PANSS) total score = 80 at Screening.
• Subject must have a score of = 4 on the following PANSS items at Screening:

P7 (hostility) G8 (uncooperativeness).

• Subject must have normal to mild symptoms on all individual items of the Simpson-Angus Scale (SAS) (< 2), Abnormal Involuntary Movement Scale (AIMS) (< 3) and Barnes Akathisia Rating Scale (BARS) (< 3) at Screening.
• Subject has been taking an antipsychotic for at least six weeks prior to Screening and has had no change in antipsychotic medication(s) (minor dose adjustments for tolerability purposes may be permitted after Medical Monitor and Sponsor review) for at least six weeks prior to Screening.

Exclusion Criteria:

• Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study, including any clinically significant hematological (including deep vein thrombosis) or bleeding disorder, renal, metabolic, endocrine, pulmonary, gastrointestinal, urological, cardiovascular, hepatic, neurologic or allergic disease (except for untreated seasonal allergies that are asymptomatic at the time of dosing).
• Subject has a disorder or history of a condition, or previous gastrointestinal surgery (eg, cholecystectomy, vagotomy, bowel resection) that may interfere with drug absorption, distribution, metabolism, excretion, gastrointestinal motility, or pH, or a history of clinically significant abnormality of the hepatic or renal system, or a history of malabsorption (uncomplicated cholecystectomy, appendectomy, and hernia repair will be acceptable).
• Subject has a DSM 5 diagnosis or presence of symptoms consistent with a DSM 5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, major depressive disorder, bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder, and posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms are not the primary focus of treatment.
• Subject answers "yes" to "Suicidal Ideation" Items 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the Columbia-Suicide Severity Rating Scale (C SSRS) at Screening (ie, in the past 1 month) or at any subsequent C SSRS assessment prior to dosing (ie since last visit).

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• placebo
single dose of placebo
• SEP-363856
single dose of SEP 363856 100 mg
• metformin
metformin-HCl 850 mg

Locations

Country	Name	City	State
United States	Hassman Research Institute	Marlton	New Jersey
United States	At Fort Lauderdale Behavioral Health Center	Oakland Park	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Sunovion

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration-time curve	area under the plasma concentration-time curve from time zero to infinity (AUC0 8) or area under the plasma concentration-time curve from time zero to a defined time (AUC0-t), if appropriate	72 hours
Primary	• maximum observed plasma concentration	maximum observed plasma concentration (Cmax).	72 hours
Secondary	area under the plasma concentration-time curve	area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUC0-last)	72 hours
Secondary	time of the maximum observed plasma concentration	time of the maximum observed plasma concentration (tmax)	72 hours
Secondary	time of last quantifiable concentration	time of last quantifiable concentration (Tlast)	72 hours
Secondary	• percentage of extrapolated AUC0-8	percentage of extrapolated AUC0-8 (%AUCextrap)	72 hours
Secondary	terminal elimination half-life	terminal elimination half-life(T1/2)	72 hours
Secondary	apparent clearance	apparent clearance (CL/F)	72 hours
Secondary	apparent volume of distribution	apparent volume of distribution (VZ/F)	72 hours
Secondary	amount excreted in urine	amount excreted in urine (Ae)	72 hours
Secondary	percentage excreted in urine	percentage excreted in urine (Fe)	72 hours
Secondary	renal clearance	renal clearance (CLR)	72 hours